Phase 3 Readout
IMCR: Phase 3 Topline: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-
October 16, 2027 · imc-f106c. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 16, 2027
- Company
- Immunocore Holdings plc (IMCR)
- Drug
- imc-f106c
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-
- Drug
- imc-f106c
- Indication
- Advanced Melanoma